Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jia-Lei Sun"'
Autor:
Ru-Chen Xu, Fu Wang, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Zhi-Yong Liu, Tao-Tao Liu, Ling Dong, Xi-Zhong Shen, Ji-Min Zhu
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-9 (2022)
Abstract Primary liver cancer (PLC) is a common gastrointestinal malignancy worldwide. While hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two major pathologic types of PLC, combined HCC and ICC (cHCC-ICC) is a relative
Externí odkaz:
https://doaj.org/article/597de4bff5e3445189bbc91861224d69
Autor:
Jia-Lei Sun, Ning-Ping Zhang, Ru-Chen Xu, Guang-Cong Zhang, Zhi-Yong Liu, Weinire Abuduwaili, Fu Wang, Xiang-Nan Yu, Xuan Shi, Guang-Qi Song, Hao Wu, Tao-Tao Liu, Xi-Zhong Shen, Bin Deng, Shu-Qiang Weng, Ling Dong, Ji-Min Zhu
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-15 (2021)
Abstract Background Tumor-associated macrophages (TAM) are immunosuppressive cells that contribute to impaired anti-cancer immunity. Iron plays a critical role in regulating macrophage function. However, it is still elusive whether it can drive the f
Externí odkaz:
https://doaj.org/article/7365da9498c843459afe01b50db19d7f
Autor:
Zhi-Yong Liu, Dan-Ying Zhang, Xia-Hui Lin, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Ru-Chen Xu, Fu Wang, Xiang-Nan Yu, Xuan Shi, Bin Deng, Ling Dong, Shu-Qiang Weng, Ji-Min Zhu, Xi-Zhong Shen, Tao-Tao Liu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib-resi
Externí odkaz:
https://doaj.org/article/027f3ea33be04898b7b15cd031fd13e2
Autor:
Qian‐Wen Rao, Shi‐Long Zhang, Meng‐Zhou Guo, Fei‐Fei Yuan, Jia‐Lei Sun, Feng Qi, Li‐Shun Wang, Bi‐Wei Yang, Jing‐Lin Xia
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8318-8332 (2020)
Abstract Identifying novel prognostic biomarkers for hepatocellular carcinoma (HCC) and then, develop an effective individualized treatment strategy remain extremely warranted. The prognostic role of sulfiredoxin‐1(SRXN1), an antioxidant enzyme, re
Externí odkaz:
https://doaj.org/article/b1a898b1497a4c7db20669cd7a2535a5
Autor:
An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li
Publikováno v:
Nanomaterials, Vol 12, Iss 18, p 3191 (2022)
Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment, has a battery of untoward side
Externí odkaz:
https://doaj.org/article/04a6bf168356413b9c00440444be74f0
Autor:
Zhi-Yong Liu, Xia-Hui Lin, Hong-Ying Guo, Xuan Shi, Dan-Ying Zhang, Jia-Lei Sun, Guang-Cong Zhang, Ru-Chen Xu, Fu Wang, Xiang-Nan Yu, Dou Wang, Shu-Qiang Weng, Xi-Zhong Shen, Tao-Tao Liu, Ling Dong, Ji-Min Zhu
Publikováno v:
International Journal of Biological Sciences; 2024, Vol. 20 Issue 7, p2763-2778, 16p
Autor:
Guang-Cong Zhang, Xiang-Nan Yu, Hong-Ying Guo, Jia-Lei Sun, Zhi-Yong Liu, Ji-Min Zhu, Tao-Tao Liu, Ling Dong, Xi-Zhong Shen, Jie Yin
Publikováno v:
Cancer Research. 83:521-537
Lipid metabolism reprogramming is a recognized hallmark of cancer cells. Identification of the underlying regulators of metabolic reprogramming in esophageal squamous cell carcinoma (ESCC) could uncover potential therapeutic targets to improve treatm
Autor:
An-Tian, Huang, Jun, Du, Zhi-Yong, Liu, Guang-Cong, Zhang, Weinire, Abuduwaili, Jia-Yan, Yan, Jia-Lei, Sun, Ru-Chen, Xu, Tao-Tao, Liu, Xi-Zhong, Shen, Ling, Dong, Ji-Min, Zhu, Yuhao, Li
Publikováno v:
Nanomaterials (Basel, Switzerland). 12(18)
Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment, has a battery of untoward side
Autor:
Weinire Abuduwaili, Xiang Wang, An-Tian Huang, Jia-Lei Sun, Ru-Chen Xu, Guang-Cong Zhang, Zhi-Yong Liu, Fu Wang, Chang-Feng Zhu, Tao-Tao Liu, Ling Dong, Ji-Min Zhu, Shu-Qiang Weng, Yuhao Li, Xi-Zhong Shen
Publikováno v:
ACS applied materialsinterfaces. 14(33)
Although sorafenib, a multi-kinase inhibitor, has provided noteworthy benefits in patients with hepatocellular carcinoma (HCC), the inevitable side effects, narrow therapeutic window, and low bioavailability seriously affect its clinical application.
Autor:
Xuan, Shi, Tao-Tao, Liu, Xiang-Nan, Yu, Asha, Balakrishnan, Hai-Rong, Zhu, Hong-Ying, Guo, Guang-Cong, Zhang, Enkhnaran, Bilegsaikhan, Jia-Lei, Sun, Guang-Qi, Song, Shu-Qiang, Weng, Ling, Dong, Michael, Ott, Ji-Min, Zhu, Xi-Zhong, Shen
Publikováno v:
Oncogene. 39(35)
Cumulative evidence suggests that microRNAs (miRNAs) promote gene expression in cancers. However, the pathophysiologic relevance of miRNA-mediated RNA activation in hepatocellular carcinoma (HCC) remains to be established. Our previous miRNA expressi